Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05078814

The Prevalence Survey of ALDH Gene Family in Patients With Peripheral Arterial Occlusive Disease or Acute Coronary Syndrome

Status
Recruiting
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Chimei Medical Center · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

Aldehyde dehydrogenase 2 (ALDH2) is an important enzyme protecting human from the accumulation of aldehyde, the main metabolites of alcohol. The deficiency of ALDH2 gene results in flush and hang over post drinking and most importantly it has been found associated with the incidence of cancer and post myocardial infarction (MI) heart failure. In the previous studies, ALDH2 decreased the ischemic territory post infarction and using a large scaled interaction of genetic variants and ALDH2 as an instrument, the threats of alcohol consumption on Asians' cardiovascular health was underscored. Furthermore, in a meta-analysis reviewing 12 case-control studies also indicated an increase of 48% risks in patients with ALDH2 deficiency. Notably, the genetic deficiency is most prevalent in Asians. In Taiwan one of every two individuals may be the victim and the high prevalence is counted as the top of the world. However, a large scaled prospective study focusing on the prevalence of ALDH2 deficiency in patients with peripheral artery occlusive disease (PAOD) or acute coronary syndrome (ACS)remains lacking.

Conditions

Interventions

TypeNameDescription
OTHERObservational researchObservational research

Timeline

Start date
2018-03-01
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2021-10-15
Last updated
2021-10-15

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT05078814. Inclusion in this directory is not an endorsement.